Recent Updates
Recently added Catalysts
CGTX Positive Sentiment

Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement

Sunday, July 27, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a poster presentation at the 2025 Alzheimer’s Association International Conference, detailing an exploratory CSF proteomic analysis from the SHINE clinical trial. This analysis focuses on a pre-specified pTau217 subgroup and identifies biomarkers associated with cognitive improvement in Alzheimer's disease patients treated with Zervimesine. The findings may contribute to advancing understanding of Alzheimer's treatment.
Price reaction · baseline $0.84 (2025-07-25 close) · 4 other CGTX headline(s) in the window, move may be shared
day 0 close
-14.9%
day 1
-20.2%
day 3 · peak
-30.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Identification of biomarkers correlated with cognitive improvement.
  • Focus on a pre-specified subgroup enhances research precision.
  • Presentation at a prominent conference highlights significance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress

Full Press Release Details

Lizama BN, Pandey K, Cho E, et al. Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement in Alzheimer’s Disease Patients Treated with Zervimesine . Poster presented at 2025 Alzheimer’s Association International Conference (AAIC) ; Toronto, Ontario, Canada

Frequently Asked Questions

What is the focus of the SHINE clinical trial?

The SHINE clinical trial focuses on Alzheimer's disease patients treated with Zervimesine.

What was presented at the 2025 AAIC?

An exploratory CSF proteomic analysis identifying biomarkers correlated with cognitive improvement.

What is pTau217?

pTau217 is a biomarker subgroup analyzed in the context of Alzheimer's disease.

How are biomarkers related to cognitive improvement?

The study identifies biomarkers that correlate with cognitive improvement in treated patients.

ShareAdd on Google
Tags: CGTX Viatris Investor Conferences Healthcare Zervimesine Alzheimer's disease biomarkers pTau217 SHINE trial
Last updated: Jul 27, 2025

Biotech snapshot

Cash runway
$34M liquidity · $1M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OxytocinPhase 2
Oxidative Stress →

Catalyst track record

+35%
best trade around CGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CGTX.

See every catalyst's timing & PoA →